Annexin Pharmaceuticals
Research Annexin Pharmaceuticals (ANNX.ST) on Bullrun: market cap SEK 78.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANNX.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 78.64M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 10.52M
- Free cash flow-SEK 10.33M
Valuation Snapshot
latest market cap is SEK 78.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 36.89M | -SEK 37.05M | n/a | -5.89 | SEK 27.40M | SEK 0 | SEK 24.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 78.64M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Annexin Pharmaceuticals
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Annexin Pharmaceuticals's market cap?
Annexin Pharmaceuticals's market capitalization is SEK 78.64M.
What does Annexin Pharmaceuticals do?
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.